Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Teva Launches Generic Fish Oil Drug

April 9, 2014 8:30 am | News | Comments

Teva Pharmaceutical Industries said Tuesday it is now selling a generic version of the heart medication Lovaza, which is used to treat high triglyceride levels. Lovaza is made from omega-3 fish oils. Read more...            


Minitron Incubator Shaker

April 8, 2014 4:27 pm | Product Releases | Comments

The Minitron incubator shaker from INFORS HT has the same characteristics as the company’s Multitron incubator shaker, but on a smaller scale.


Update: Arkansas AG Files Petition on Risperdal Ruling

April 8, 2014 1:47 pm | by Andrew DeMillo | News | Comments

Arkansas Attorney General Dustin McDaniel asked the state Supreme Court to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson, saying justices did "significant harm" to the state and broke from 170 years of precedent. Read more...


Curis, Debiopharm Report Anti-Tumor Activity, Synergy with Debio 0932

April 8, 2014 1:39 pm | News | Comments

Curis Inc. and Debiopharm Group announced the presentation of data for Debio 0932 at the Annual Meeting of the AACR that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of NSCLC and RCC. Read more...


USPTO Grants Hovione a New Inhaler Patent

April 8, 2014 1:27 pm | News | Comments

Hovione announced that the United States Patent and Trademark Office has granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione less than three years after the patent was filed and after just one Office Action– unusual speed for an inhaler application. Read more...


Calithera Glutaminase Inhibition Assay Shows Promise

April 8, 2014 1:17 pm | News | Comments

Calithera Biosciences, a clinical-stage biotechnology company focused on the development of novel cancer therapeutics, announced that data for its lead clinical candidate, CB-839, were featured in two presentations at the 2014 AACR Annual Meeting. Read more...


Pharmacyclics Files Imbruvica Supplemental NDA

April 8, 2014 12:45 pm | News | Comments

Pharmacyclics Inc. announced that it has submitted a sNDA to the FDA based on data from the Phase 3 RESONATE study, a head-to-head comparison of Imbruvica versus ofatumumab in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Read more... 


Zohydro Maker Sues to Block Massachusetts Ban

April 8, 2014 12:27 pm | News | Comments

The maker of Zohydro, a controversial new prescription painkiller, has filed a lawsuit in the U.S. District Court on Monday seeking to block Massachusetts' ban on local doctors prescribing and dispensing the drug. Read more...    


Novartis Partners to Provide Antimalarial Treatments in Zambia

April 8, 2014 10:36 am | News | Comments

Novartis announced that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign. Read more...          


EU Approves Two-Dose Gardasil for Early Teens

April 8, 2014 10:29 am | News | Comments

Sanofi Pasteur MSD announced that the European Commission has granted marketing authorization for its quadrivalent HPV vaccine, Gardasil, for a two-dose schedule at zero and six months in children aged from nine to 13 years. Read more...   


Merck Serono Begins Phase 3 NSCLC Trial of Tecemotide

April 8, 2014 10:19 am | News | Comments

Merck Serono announced the initiation of the Phase 3 START2 study, designed to assess the efficacy and safety of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide in patients with advanced Stage III non-small cell lung cancer. Read more...


Alkermes' Schizophrenia Drug Hits Key Phase 3 Endpoints

April 8, 2014 10:05 am | News | Comments

Alkermes plc announced positive top-line results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Read more...                 


Takeda, Lilly Face Penalty over Actos Cancer Cases

April 8, 2014 9:25 am | by Yuri Kageyama, AP Business Writer | News | Comments

A U.S. jury ordered Japanese drugmaker Takeda Pharmaceutical Co. and Eli Lilly and Co. to pay $9 billion in punitive damages over a diabetes medicine linked to cancer. The drug companies said they will "vigorously challenge" the decision. Read more...


New Drug May Benefit Head, Neck Cancer Patients

April 8, 2014 8:30 am | News | Comments

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) may benefit from treatment with the investigational drug dacomitinib if their cancer has no defects in a cell signaling pathway called the PI3K pathway and no signs of excessive inflammation. Read more...


Gilead Hep C Combo Gets Breakthrough Therapy Status, Priority Review from FDA

April 7, 2014 2:21 pm | News | Comments

Gilead Sciences Inc. announced that the FDA has granted priority review and a Breakthrough Therapy designation to the comapny's fixed-dose combination of ledipasvir and sofosbuvir for the treatment of chronic hepatitis C genotype 1. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.